甲磺酸奥希替尼片致心力衰竭1例分析

doi:10.19803/j.1672-8629.20240786

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (11): 1300-1303.
DOI: 10.19803/j.1672-8629.20240786

甲磺酸奥希替尼片致心力衰竭1例分析

孔应利¹, 辛鑫园¹, 时绘绘¹, 赵紫楠², 张亚同^2*

¹邢台市中心医院药剂科,河北邢台 054000;
²北京医院药学部,国家老年医学中心,北京 100730

收稿日期:2024-10-11 出版日期:2025-11-15 发布日期:2025-11-14
通讯作者: ^*张亚同,男,硕士,主任药师,临床药学。E-mail: Zyt2002888@qq.com
作者简介:孔应利,女,硕士,主管药师,临床药学。
基金资助:
邢台市重点研发计划自筹项目（2023ZC106）

One Case of Heart Failure Caused by Osimertinib Mesylate Tablets

KONG Yingli¹, XIN Xinyuan¹, SHI Huihui¹, ZHAO Zinan², ZHANG Yatong^2*

¹Department of Pharmacy, Xingtai Central Hospital, Xingtai Hebei 054000, China;
²Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Beijing 100730, China

Received:2024-10-11 Online:2025-11-15 Published:2025-11-14

摘要/Abstract

摘要： 目的探讨甲磺酸奥希替尼片（以下简称“奥希替尼”）致心力衰竭的临床特点及作用机制,为临床用药提供参考。方法分析1例59岁肺腺癌患者服用奥希替尼后出现心力衰竭,采用Naranjo's（诺氏）评分及结合相关文献,探讨可能致心衰的药物、发生原因及防治措施。结果患者发生的心力衰竭很有可能与奥希替尼有关,停药并积极抗心衰治疗后,患者心功能基本恢复。结论奥希替尼引起心力衰竭相对较少,需注意奥希替尼可在用药数天至数月后引起心力衰竭。

关键词: 甲磺酸奥希替尼片, 心力衰竭, 肺腺癌, 药品不良反应

Abstract: Objective To analyze the clinical characteristics and potential mechanisms of heart failure caused by osimertinib mesylate tablets (osimertinib) in order to provide a reference for safe use of osimertinib and for clinical management. Methods The clinical data of a 59-year-old patient with lung adenocarcinoma who developed heart failure after taking osimertinib was analyzed. Combined with related literature, the Naranjo's score was used to find out about the drugs that might have caused heart failure, causes of occurrence, and measures for prevention and treatment. Results It was very likely that osimertinib caused heart failure in this patient. After discontinuation of osimertinib and management of heart failure, the patient's cardiac function significantly improved. Conclusion Despite the scarcity of cases of heart failure caused by osimertinib, clinicians should be aware that osimertinib can cause heart failure a few days to several months after administration.

Key words: Osimertinib Mesylate Tablets, Heart Failure, Lung Adenocarcinoma, Adverse Drug Reactions

中图分类号:

孔应利, 辛鑫园, 时绘绘, 赵紫楠, 张亚同. 甲磺酸奥希替尼片致心力衰竭1例分析[J]. 中国药物警戒, 2025, 22(11): 1300-1303.

KONG Yingli, XIN Xinyuan, SHI Huihui, ZHAO Zinan, ZHANG Yatong. One Case of Heart Failure Caused by Osimertinib Mesylate Tablets[J]. Chinese Journal of Pharmacovigilance, 2025, 22(11): 1300-1303.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240786

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I11/1300

参考文献

[1] LEITER A, VELUSWAMY RR, WISNIVESKY JP.The Global Burden of Lung Cancer: Current Status and Future Trends[J]. Nature Reviews Clinical Oncology, 2023, 20(9): 624-639.
[2] RICOTTI A, SCIANNAMEO V, BALZI W, et al.Incidence and Prevalence Analysis of Non-Small-Cell and Small-Cell Lung Cancer Using Administrative Data[J]. International Journal of Environmental Research and Public Health, 2021, 18(17): 9076.
[3] MOK TS, WU YL, AHN MJ, et al.Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer[J]. The New England Journal of Medicine, 2017, 376(7): 629-640.
[4] ZHANG CH, CUI XK, PENG TT, et al.Efficacy and Safety of Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer: a Meta-Analysis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(2): 178-183.
[5] SORIA JC, OHE Y, VANSTEENKISTE J, et al.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. The New England Journal of Medicine, 2018, 378(2): 113-125.
[6] FU ZL, SUN HY.Literature Review of Osimertinib-Associated Heart Failure[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2023, 32(9): 673-678.
[7] KUNIMASA K, KAMADA R, OKA T, et al.Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated with Osimertinib[J]. JACC CardioOncol, 2020, 2(1): 1-10.
[8] PATEL K, HSU KY, LOU K, et al.Osimertinib-Induced Biventricular Cardiomyopathy with Abnormal Cardiac MRI Findings: a Case Report[J]. Cardiooncology, 2023, 9(1): 38.
[9] LU SX, XING YL, MIAO Y, et al.Osimertinib Induced Adverse Cardiac Events: a CaseReport[J]. Journal of Geriatric Cardiology, 2023, 20(9): 702-706.
[10] ANANDK, ENSOR J, T RACHTENBER GB, et al. Osimertinib-Induced Cardiotoxicity: a Retrospective Review of the FDA Adverse Events Reporting System (FAERS)[J]. JACC Cardio Oncol, 2019, 1(2): 172-178.
[11] FU XW.Literature Analysis of Osimertinib Adverse Reactions[J].Tianjin Pharmacy(天津药学), 2022, 34(4): 47-49, 54.
[12] LOU AQ, ZHENG JC.Risk Analysis of Cardiotoxicity from Osimertinib Based on FAERS[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2022, 25(9): 788-792.
[13] DONG SC, HUO XD, SUN C, et al.Based on Real-World Monitoring Data to Explore and Analyze the Adverse Reaction Signals of Osimertinib after Marketing[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(6): 642-646.
[14] WANG L, ZHANG L, ZHU LN, et al.Research Progress of Osimertinib Related Cardiotoxicity[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2023, 43(13): 1516-1520.
[15] NARANJO CA, BUSTO U, SELLER SEM, et al.A Method for Estimating the Probability of Adverse Drug Reactions[J]. Clinical Pharmacology and Therapeutics,1981, 30(2): 239-245.
[16] BABAR T, BLOMBERG C, HOFFNER E, et al.Anti-HER2 Cancer Therapy and Cardiotoxicity[J]. Current Pharmaceutical Design, 2014, 20(30): 4911-4919.
[17] LIU S, LI S, HAI J, et al.Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib[J]. Clinical Cancer Research, 2018, 24(11): 2594-2604.
[18] SHYAM SS, SHARMA UC, POKHAREL S.Adverse Effects of Tyrosine Kinase Inhibitors in Cancer Therapy: Pathophysiology, Mechanisms and Clinical Management[J]. Signal Transduction and Targeted Therapy, 2023, 8(1): 262.
[19] GOMEZ JA.Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors: Novel Mechanisms, Predictors of Hypertension and Management Strategies[J]. American Heart Journal Plus, 2022, 17: 100144.
[20] BYUN JY, HAN S, LIU Y, et al.Sex-Specific Risk of Heart Failure and Acute Myocardial Infarction Associated with Osimertinib in Older Patients with Non-Small Cell Lung Cancer[J]. Therapeutic Advances in Medical Oncology, 2024, 16: 17588359241264721.
[21] MADONNA R, PIERAGOSTINO D, CUFARO MC, et al.Sex-Related Differential Susceptibility to Ponatinib Cardiotoxicity and Differential Modulation of the Notch1 Signalling Pathway in a Murine Model[J]. Journal of Cellular and Molecular Medicine, 2022, 26(5): 1380-1391.
[22] LYON AR, LÓPEZ-FERNÁNDEZ T, COUCH LS, et al. 2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association(EHA), the European Society for Therapeutic Radiology and Oncology(ESTRO) and the International Cardio-Oncology Society(IC-OS)[J]. European Heart Journal, 2022, 43(41): 4229-4361.
[23] MIZUNO T, SAKAI T, TANABE K, et al.Identification of Target Small Molecule Tyrosine Kinase Inhibitors that Need Monitoring and Clinical Application of Protocol for Early Detection of Cancer Therapeutics-Related Cardiac Dysfunction Using Signal Detection: An Investigation of Real World Data[J]. Journal of Oncology Pharmacy Practice, 2021, 27(4): 804-814.
[24] XU WJ, PENG Q, HUANG HY, et al.285 Cases of Adverse Drug Reactions Related to New Antineoplastic Drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(2): 199-203, 210.

甲磺酸奥希替尼片致心力衰竭1例分析

One Case of Heart Failure Caused by Osimertinib Mesylate Tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	蒋晓峰, 杨淑婷, 白丽琴, 戚俊, 何建雄, 陈文戈, 梁祖红, 李渔, 余晓霞. 医疗机构制剂不良反应监测与评价系统构建及初步实践[J]. 中国药物警戒, 2025, 22(9): 1008-1011.
[2]	蔡杰, 韩陈媛, 江君微. 887例静脉滴注抗菌药物不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1018-1023.
[3]	郑金凤, 吴佳妮, 林京玉, 杨雪卿. 222例口服凝血因子Xa抑制剂不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1024-1028.
[4]	谢加力, 荀艳, 陶云松, 章圣朋. 211例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1029-1033.
[5]	刘芹, 章嘉一, 吴烜, SOANES Nigel. 基于生成式人工智能大语言模型的文献来源药品不良反应报告自动生成平台研究与应用[J]. 中国药物警戒, 2025, 22(9): 1040-1044.
[6]	李舒悦, 邱慧颖, 吴佳琪, 高君伟. 炔雌醇环丙孕酮片致急性髓系白血病患者血小板减少期间血栓形成2例分析[J]. 中国药物警戒, 2025, 22(9): 1045-1048.
[7]	李丹, 阳雄文, 陈丹君, 付成效, 阳波. 苯扎贝特片致慢性肾病患者横纹肌溶解1例分析[J]. 中国药物警戒, 2025, 22(9): 1049-1050.
[8]	钱凤丹, 张立超, 贡翊斐. 注射用尖吻蝮蛇血凝酶致严重过敏性休克1例分析[J]. 中国药物警戒, 2025, 22(9): 1051-1053.
[9]	邵一帆, 陈秋岑, 翟惠奇, 吴伟, 褚庆民. 铝碳酸镁咀嚼片致严重过敏反应1例分析[J]. 中国药物警戒, 2025, 22(9): 1054-1056.
[10]	魏盈, 李文凤, 张宇飞, 侯欣, 杨彦伟, 樊永丽. 度伐利尤单抗注射液致脓疱型银屑病1例分析[J]. 中国药物警戒, 2025, 22(9): 1057-1060.
[11]	李明颖, 张晓霞, 孙晓黎, 赵燕, 何苗, 李艳玲, 段薇, 杨鸥. 舒更葡糖钠对腹腔镜全盆底重建术后患者恢复的影响[J]. 中国药物警戒, 2025, 22(8): 896-901.
[12]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[13]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[14]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[15]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.